Many consider an Hb level <10.0 g/dL to be an epiphenomenon associated with poor therapeutic outcomes [3, 15], and thus, transfusion aimed at correcting anemia is not expected to provide clinical benefits. This evidence concerns the gene GSTM1 and anemia (phenotype).